Source comparison
CJC-1295 MK-677 Stack: Research Design Comparison
Research designs for peptide stacks vary significantly in structure, monitoring intensity, and endpoint prioritization. The table below compares three validated approaches used in published studies examining GH secretagogue combinations. High-Intensity Peak Re
This comparison does not assign a generated winner or score.
- Research designs for peptide stacks vary significantly in structure, monitoring intensity, and endpoint prioritization. The table below compares three validated approaches used in published studies examining GH secretagogue combinations.
- High-Intensity Peak Response
- 60mcg/kg (≈4mg) subcutaneous twice weekly
- 25mg oral daily (evening)
- Peak IGF-1 response measured at week 2 and week 4
- IGF-1, glucose, insulin every 2 weeks
- 4–8 weeks with 4-week washout
- Maximizes IGF-1 elevation (80–110% above baseline) but increases insulin resistance risk—best for short observation windows where glucose control is tightly managed
- Moderate-Intensity Sustained
- 30mcg/kg (≈2mg) subcutaneous once weekly
- 12.5mg oral daily (evening)
- Sustained IGF-1 ≥50% above baseline across 12 weeks
- IGF-1, HbA1c, IGFBP-3 every 4 weeks; glucose every 2 weeks
- 12 weeks on, 4 weeks off
- Balances efficacy and tolerability—lower glucose disruption while maintaining IGF-1 response suitable for body composition or tissue repair studies
- Pulsed CJC / Continuous MK-677
- 30mcg/kg (≈2mg) subcutaneous 2 weeks on / 2 weeks off
- 15mg oral daily continuously
- IGF-1area under curve (AUC) across 16-week period
- IGF-1 every 2 weeks; glucose, receptor sensitivity markers every 4 weeks
- 16 weeks with built-in washout intervals
- Prevents GHRH receptor desensitization through pulsed exposure while maintaining ghrelin pathway activation—optimal for protocols extending beyond 12 weeks
- The comparison table illustrates that stacking strategy must align with study objectives. Peak-response designs using higher doses of both compounds deliver maximum IGF-1 elevation but compress the observation window due to glucose and receptor desensitization concerns. Moderate-intensity protocols extend study duration while preserving measurable anabolic endpoints. Pulsed designs sacrifice peak response for sustained receptor sensitivity, which matters most in trials examining long-term adaptation rather than acute hormone dynamics.